Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siTLR3-R9
- Development stage
- Preclinical
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravesical
01
Overview
siTLR3-R9 is a preclinical small interfering RNA (siRNA) nanoparticle formulation designed for the treatment of inflammatory bladder diseases, such as interstitial cystitis. Developed by researchers at West China Hospital of Sichuan University, the therapeutic consists of siRNA targeting Toll-like receptor 3 (TLR3) complexed with nona-arginine (R9), a cell-penetrating peptide, to form self-assembled nanoparticles. To prevent rapid clearance by urine, the nanoparticles are co-administered within a mucoadhesive hydrogel microsphere system (composed of polyvinyl alcohol, gelatin, citric acid, and tannic acid) that physically anchors the siRNA to the bladder wall. In preclinical models of cyclophosphamide-induced cystitis, intravesical instillation of this formulation successfully silenced TLR3 expression, leading to reduced bladder inflammation, downregulation of pro-inflammatory cytokines (TNF-alpha, IL-6), and restoration of the urothelial barrier.
- Other names
- siTLR3-R9 NPssiTLR-3-R9 NPssiTLR 3-R9 NPssiTLR3-R9 nanoparticlessiTLR-3-R9 nanoparticlessiTLR 3-R9 nanoparticles
02
Targets
TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on siTLR3-R9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siTLR3-R9.